Rheumatoid Arthritis
Introduction
Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab
JAK/STAT Pathway: Communication From Transmembrane Receptors to the Nucleus
Currently Available JAK Inhibitors for RA
Early vs Delayed Start of Baricitinib in Patients Naive to MTX Treatment
MTX Withdrawal in Patients Who Achieve LDA With Tofacitinib MR 11 mg QD + MTX
Efficacy and Safety of Peficitinib in Patients Who Had an Inadequate Response to MTX
Efficacy and Safety of Peficitinib in Patients Who Had an Inadequate Response to DMARDs
FINCH1: Efficacy and Safety of Filgotinib in MTX-IR Patients
FINCH3: Efficacy and Safety of Filgotinib in MTX-Naive Patients
FINCH2: Subgroup Analyses
Switching Between Upadacitinib and ADA Following Initial Non-Response
Upadacitinib SELECT Trials: 48-Week Results
Fenebrutinib Compared to PBO and ADA in MTX-IR or TNF-IR Patients
Safety and Efficacy of LY3337641 in Patients With RA: Phase 2 Study
Subcutaneous Administration of Infliximab Biosimilar (CT-P13)
Concluding Remarks
Abbreviations
Abbreviations (cont)